Purdue’s Head Of R&D Has Broad Remit To Bring In New Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
Newly appointed senior VP-R&D Alan Dunton is charged with curing the firm's dependency on pain products.
You may also be interested in...
Purdue CEO: The Year For Transformative M&A Is Here
The private specialty pharma is shopping for a transformative deal or a series of smaller deals that will diversify the company into a new area outside of pain and CNS disorders, CEO Mark Timney says during interview.
People In The News: CEO Changes At Avalanche, Neurogastrx, Chase, Mannkind
FTC's Bureau of Economics adds two officials with pharma expertise; more personnel changes in this month's column.
Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.
While other companies have been hit with heftier fines for falsely marketing their drugs, Purdue Pharma's $700.6 million agreement with the Department of Justice over OxyContin promotions has had a profound impact on the management of the company, with guilty pleas from two of the firm's top executives